Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
NCT03281538
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
288
Enrollment
INDUSTRY
Sponsor class
Conditions
Uremic Pruritus
Interventions
DRUG:
CR845
Sponsor
Cara Therapeutics, Inc.